---
layout: default
title: Alpha -Tocopherol Acetate D- Calcium Carbonate Cal
parent: 僅模型預測 (L5)
nav_order: 220
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Acetate D- Calcium Carbonate Cal
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multivitamin-Mineral Complex (15-Component): Evaluation Not Possible — Insufficient Data

## One-Sentence Summary

This entry represents a 15-component vitamin and mineral combination (including Vitamins B1, B2, B3, B6, B9, B12, C, D3, E, plus calcium, iron, zinc, iodine, and choline), consistent with a comprehensive prenatal or therapeutic multivitamin formula.
The TxGNN model returned **no predicted indications** for this combination, and the compound is currently **not registered in Taiwan**.
As a result, a standard drug repurposing evaluation cannot be completed with the available data.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None recorded |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only; no actual predictions generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN repurposing prediction was generated for this entry. This is most likely because the query submitted to the pipeline was a **multi-component mixture string** rather than a single active pharmaceutical ingredient (API), which the TxGNN knowledge graph cannot process as a unified entity.

The 15 components — spanning water-soluble vitamins (B-complex, vitamin C), fat-soluble vitamins (D3, E), macrominerals (calcium), trace minerals (iron, zinc, iodine), and a phospholipid precursor (choline) — are each individually well-characterised in DrugBank and the TxGNN knowledge graph. However, the pipeline requires a single DrugBank ID as input. No DrugBank ID was resolved for this compound string, confirming the mapping failure.

To unlock a meaningful repurposing analysis, the pipeline would need to be re-run on each individual component separately, or on the most pharmacologically active constituent of interest (e.g., cholecalciferol, folic acid, or cyanocobalamin), before combining results.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this combination as a unified entity.

> **Note:** Individual components (e.g., folic acid for neural tube defect prevention, cholecalciferol for bone health) have extensive clinical trial records. A component-level search is recommended.

---

## Literature Evidence

Currently no related literature available for this specific 15-component mixture as a single entity.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** No Taiwan TFDA monograph was retrieved (market status: not registered). For individual component safety data, consult DrugBank entries for each ingredient.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline failed to generate any repurposing predictions because the query was submitted as a multi-component ingredient string without a resolvable DrugBank ID, making systematic evaluation impossible at this time.

**To proceed, the following is needed:**

- **Decompose the query**: Re-run TxGNN predictions on each of the 15 individual active ingredients separately (D-alpha-tocopherol acetate, cholecalciferol, folic acid, cyanocobalamin, etc.)
- **Identify the lead compound**: Determine which single component is the primary subject of the repurposing hypothesis, then generate a targeted Evidence Pack for that ingredient
- **Resolve DrugBank IDs**: Map each ingredient to its individual DrugBank ID (e.g., folic acid → DB00158, cholecalciferol → DB00169) to enable knowledge graph traversal
- **Clarify clinical context**: Determine whether this formulation is intended as a prenatal supplement, a therapeutic micronutrient replacement, or another clinical application — this will guide which component to prioritise
- **Taiwan registration check**: If market entry is the goal, confirm whether individual components or the full combination requires NDA filing with TFDA
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

